Custom Search

Rituximab News

FDA Warns of Safety Concern Regarding Rituxan in New Patient Population

The Food and Drug Administration (FDA) is alerting health care professionals and patients treated with Rituxan (rituximab) to reports of an emerging risk of a serious side effect in patients receiving or who have used Rituxan....

MabThera First-line Treatment Helps Patients With Indolent Lymphoma Live Longer

Roche has announced exciting results from a pivotal phase III study that has followed the outcome of patients with indolent non-Hodgkin's lymphoma (NHL) treated with MabThera over four years ago.

Subsequent Course of Rituxan(R) Improved Outcomes in Rheumatoid Arthritis Patients Who Inadequately Responded to TNF Antagonist Therapy

Preliminary Safety Data on TNF Antagonist Use Following Rituxan Treatment Also Being Presented at the American College of Rheumatology Meeting

Genentech, Biogen's Rituxan may help skin disease

The cancer drug Rituxan may cure a rare but potentially fatal skin disorder characterized by blistering lesions that do not heal, a study showed on Wednesday.

Clinical Data Inc., Signs Exclusive License for Monoclonal Antibody Pharmacogenetic Patent Portfolio

Clinical Data Inc. announced today that it has signed an exclusive worldwide license to an extensive portfolio of patents related to a variation in the Fc gamma receptor IIIA gene.

Displaying results 6 to 10 out of 24

< Previous






Next >

Use of this site is subject to the following terms of use